Posts

I&I startup Attovia files to go public as biotech listings momentum builds

on
Attovia Therapeutics, a clinical-stage biopharmaceutical company focused on immune-mediated and inflammatory (I&I) diseases, filed an S-1 registration statement with the U.S. Securities and Exchange Commission on July 14, 2026, to pursue an initial public offering (IPO) on the Nasdaq Global Market under the ticker symbol "ATTO." The company aims to raise up to $100 million through the offering, building on over $255 million in prior private funding from investors including Frazier Life Sciences, Deep Track Capital, Goldman Sachs, and venBio. Attovia is advancing an IL-31–targeting pipeline led by ATTO-1310, a fusion protein for chronic pruritus and high-itch atopic dermatitis, alongside bispecific and trispecific candidates in preclinical development. The filing arrives amid a strong 2026 biotech IPO environment, with Attovia and Braveheart Bio among the latest wave of startups signaling readiness to list as investor appetite for immunology and platform-driven biotechs im...

Eli Lilly partners with Oura to support GLP-1 patients via smart‑ring tools

on

Insilico and Bora Unveil AI-Driven Manufacturing and CDMO Platform Plans

on

Celcuity Wins FDA Approval for First-in-Class Breast Cancer Drug Revtorpyk (gedatolisib)

on

Kelun's sac-TMT scores win in first-line PD-L1-negative NSCLC population missing from Merck's KEYTRUDA phase 3 program

on

AAIC 2026：Biogen公布抗tau反义寡核苷酸药物详细数据，抗tau领域初现曙光

on

Questions linger over Biogen's tau drug for Alzheimer's, as low dose reports better results

on

Autonomous Healthcare Receives FDA De Novo Marketing Authorization for Syncron-E Ventilator Waveform Analysis Software

on

Eisai, Biogen scoop up subQ Leqembi starter‑dose nod – FDA greenlights subcutaneous lecanemab initiation for early Alzheimer’s disease

on

Chai Discovery raises $400M Series C for AI molecule models used by Lilly, Novartis and Pfizer

on

Huyabio scores with Opdivo combo in 'milestone' skin cancer trial

on

AstraZeneca licenses EGFR lung cancer drug Zegfrovy from spinoff Dizal for up to $1.5B

on

Post-Hoc Live: What's making biotech IPOs work again?

on